Skip to main content

Of all used cars, this Tesla model sells the fastest

It’s early, but there are signs Tesla’s Model 3 could be as exceptional in the used market as it has been in the new-car world.

The sedan has sold at volumes no other electric vehicle has come close to reaching, turning Tesla into the most valuable auto company in the world. But it takes a while to see how well a car performs on the used market — owners typically hold onto their wheels for at least a few years.

Car-shopping websites still have small samples sizes to work with for how used Model 3s are doing, but so far the data are encouraging. The sedans are selling quickly once owners list them for sale, and TrueCar Inc.’s ALG unit sees their presence in the premium-electric vehicle market having a dramatic impact on the segment.

“If you’re looking for a used Audi A4, you have other comparable options like the BMW 3 Series, Mercedes-Benz C-Class and Lexus IS,” said George Augustaitis, director of automotive industry and economic analysis at CarGurus Inc. “If you’re looking for a Model 3, there’s no substitute.”

Early plug-in models such as the Nissan Leaf and BMW i3 depreciated much faster than conventional cars. Demand was low, driving range was limited and battery degradation was a concern.

Low residual value — the amount cars are worth after a few years of ownership — was one of many factors holding back wider adoption of EVs. But ALG’s outlook is for vast improvement. The 64-year-old company formerly known as Automotive Lease Guide forecasts that the premium electric-car segment will go from currently having the lowest auction-value retention after three years to the fourth-highest 36 months from now.

Used Model 3s took just 29.3 days to sell on average from March through June, according to iSeeCars.com. The Tesla sedan was the fastest-selling used car the vehicle-listing aggregator tracked during that span.

Tesla’s ability to deliver over-the-air software updates are likely helping its cause.

“You’ll frequently hear people say, ‘The car I own is better than the one I purchased,’” said Gene Munster, a managing partner at venture capital firm Loup Ventures.

Tesla started production of the Model 3 in the second half of 2017, but it took the company months to ramp up output. It also didn’t begin offering leases until April 2019.

“There still aren’t a lot of Teslas in the aftermarket,” said George Chamoun, chief executive officer of ACV Auctions. Some independent used-car dealers don’t sell them, but he expects this to change.

ACV sold triple the number of Teslas in July compared with the beginning of this year, and the average number of bids for the cars are 20% more than for the rest of the company’s inventory.

“Demand is outpacing the limited supply,” CarGurus’ Augustaitis said of the Model 3. “Its range and tech and price point are still unique.”

More must-read tech coverage from Fortune:



from Fortune https://ift.tt/2EuALnp
Labels:

Comments

Post a Comment

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $
Post a Comment
Read more

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be
Post a Comment
Read more